Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

TYRA

Tyra Biosciences (TYRA)

Tyra Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:TYRA
DateTimeSourceHeadlineSymbolCompany
23/01/202510:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
23/01/202500:00PR Newswire (US)Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers SymposiumNASDAQ:TYRATyra Biosciences Inc
11/01/202500:00PR Newswire (US)Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)NASDAQ:TYRATyra Biosciences Inc
10/12/202409:42Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
07/12/202413:30Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TYRATyra Biosciences Inc
07/12/202413:30Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TYRATyra Biosciences Inc
06/12/202408:21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
03/12/202411:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
21/11/202408:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
20/11/202413:31Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TYRATyra Biosciences Inc
15/11/202409:52Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
14/11/202408:05PR Newswire (US)Tyra Biosciences to Present at Upcoming Investor ConferencesNASDAQ:TYRATyra Biosciences Inc
08/11/202408:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
08/11/202408:05PR Newswire (US)Tyra Biosciences Reports Third Quarter 2024 Financial Results and HighlightsNASDAQ:TYRATyra Biosciences Inc
31/10/202407:01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
29/10/202408:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
28/10/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
28/10/202422:00PR Newswire (US)Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)NASDAQ:TYRATyra Biosciences Inc
25/10/202423:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
25/10/202409:21PR Newswire (US)Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)NASDAQ:TYRATyra Biosciences Inc
24/10/202407:05PR Newswire (US)Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ETNASDAQ:TYRATyra Biosciences Inc
23/10/202412:15Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TYRATyra Biosciences Inc
23/10/202411:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TYRATyra Biosciences Inc
23/10/202411:47Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TYRATyra Biosciences Inc
19/10/202407:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
11/10/202423:00PR Newswire (US)Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)NASDAQ:TYRATyra Biosciences Inc
19/09/202406:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
19/09/202405:59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
19/09/202405:56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
19/09/202405:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:TYRA